Practice Parameter Initiation Of Treatment For Parkinson Disease
Category : Health » Parkinson Disease
. Parameter on medical treatment of Parkinson's disease (PD) concluded that levodopa . combined treatments after an average follow-up of 8.2 years. .
Download File
Free PDF eBooks Download
Health
Parkinson Disease
Content Summary :
Introduction Parkinson’s disease (PD) is a common neurodegenerative disorder with an estimated prevalence of 100 to-200/100,000 population. As it is a progressive disorder that results in significant disability 10 to15 years after onset, the financial and social burden of this disease is considerable, (1) particularly with our aging population. The worldwide cost of medications alone is estimated to be US $11 billion per year, with costs increasing three to five fold for patients with advanced disease. (2,3) Ideally, if a drug were available, initial treatment of PD should slow disease progression. Once symptomatic benefit is required, treatment should reduce disability without inducing complications over the long term. Based on these goals, there are several controversial questions regarding initial PD treatment. These include: Does selegiline have neuroprotective benefit in the treatment in early PD? What is the best agent to initiate specific dopaminergic therapy in early PD? Finally, is there a benefit of sustained-release levodopa over immediate release levodopa in the treatment of early PD?
Favorite Parkinson Disease PDF File
Department of Neurology Department of Neurology. Parkinson Center of Oregon . No part of this book may be reproduced or transmitted in any form or by any .
Adult Stem Cells Treat Parkinson 39 s in Humans and Animals . This treatment provided. an average 61 improvement in motor function. .
primary treatment for symptomatic Parkinson 39 s disease . are effective treatments for these patients. 30. Nonpharmacologic Treatment .
set Parkinson 39 s starting before age 21 years fre . Parkinson 39 s Disease. Treatment Complications. Exercise and Nutrition. The Workplace .
new treatment opportunities. and therapies available to. people with Parkinson 39 s disease. . in Parkinson 39 s. Treatment. SPRING CONFERENCE Approved for 2 .